Moderna (MRNA) Saham Harga

Moderna Harga

NYSE·DITUTUP
221,72
​
Pasar ditutup

Pendapatan tumbuh 112,0% per tahun selama 11 tahun terakhir menjadi 1,94 miliar USD. margin bersih Moderna saat ini -145,2%, turun dari 68,8% beberapa tahun lalu. Target harga median analis adalah 57,12 USD, di bawah harga saat ini sebesar 74,2%. Dari 33 analis, 14 merekomendasikan beli — konsensus keseluruhan Tahan.

Harga saham Moderna

Akses data ini lewat Eulerpool API

100.000 permintaan/bulan gratis · tanpa kartu

Model bisnis dan analisis saham Moderna

Moderna Inc adalah perusahaan bioteknologi asal Amerika Serikat yang mengkhususkan diri dalam pengembangan terapi dan vaksin berbasis teknologi mRNA. Perusahaan ini didirikan pada tahun 2010 oleh sekelompok peneliti yang dipimpin oleh Noubar Afeyan, dengan kantor pusat di Cambridge, Massachusetts.

Pertanyaan yang sering diajukan tentang saham Moderna

Moderna Inc is a biotechnology company with a business model that focuses on the development and commercialization of mRNA-based therapeutics and vaccines. The company utilizes mRNA technology to create personalized medicine and improve healthcare outcomes. With an emphasis on infectious diseases, rare diseases, and oncology, Moderna Inc leverages its platform to develop a diverse pipeline of innovative treatments. By harnessing the potential of mRNA, Moderna Inc aims to revolutionize the way diseases are prevented and treated, offering new hope and possibilities for patients globally.

Moderna Inc is primarily active in the biotechnology and pharmaceutical industries.

Moderna Inc faces competition from various companies in the market, including established pharmaceutical giants such as Pfizer, Johnson & Johnson, and AstraZeneca. These competitors also focus on developing and distributing vaccines and therapeutics, much like Moderna Inc. However, Moderna Inc stands out for its pioneering messenger RNA (mRNA) technology, which has gained significant attention and recognition. With its innovative approach and potential for addressing unmet medical needs, Moderna Inc continues to position itself as a prominent player in the biopharmaceutical industry and compete against other industry leaders in the market.

Moderna Inc, a leading biotechnology company, was founded in 2010. Headquartered in Cambridge, Massachusetts, Moderna specializes in the development of mRNA-based medicines and therapies. By utilizing the potential of messenger RNA (mRNA) technology, the company aims to revolutionize the field of medicine. Moderna has a diverse pipeline of investigational programs, targeting various diseases, including infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders. The company's commitment to innovation and cutting-edge research has attracted strategic collaborations with renowned organizations and industry leaders. With its groundbreaking approach and promising advancements, Moderna Inc continues to make significant contributions to the biomedical field.

Moderna Inc, a renowned biotechnology company, has achieved several significant milestones. Notably, Moderna became the first company to release an mRNA-based vaccine authorized for emergency use against COVID-19, known as the Moderna COVID-19 Vaccine. This breakthrough marked a monumental achievement in the fight against the global pandemic. Additionally, Moderna has made remarkable progress in advancing mRNA-based therapies for various diseases, including cancer and rare genetic disorders. Through strategic collaborations and cutting-edge research, Moderna has demonstrated its commitment to revolutionize medicine by harnessing the power of mRNA technology. Moderna Inc's dedication to innovation and groundbreaking achievements position it as a leading player in the biotech industry.

Moderna Inc is primarily present in several countries and regions worldwide. The company has its headquarters in Cambridge, Massachusetts, United States. Apart from the US, Moderna Inc has a notable presence in various countries and regions such as Europe, including the United Kingdom, Germany, France, and Switzerland. Additionally, Moderna Inc operates in Asia, with a presence in Japan and South Korea. The company also has collaborations and partnerships with organizations and institutions globally, enabling its presence in diverse regions for the development and distribution of its innovative mRNA-based vaccines and therapies.

Moderna Inc represents a commitment to pioneering transformative medicines based on messenger RNA (mRNA) technology. The company's corporate philosophy centers around innovation, collaboration, and patient-focused progress. Moderna believes in leveraging its proprietary mRNA platform to develop a vast range of potential therapeutics and vaccines to tackle various diseases. The company strives to address unmet medical needs and improve global healthcare through its cutting-edge research and development efforts. Moderna's dedication to scientific excellence, forward-thinking strategies, and ongoing partnerships positions it as a leader in the biotechnology industry, driving breakthroughs and shaping the future of medicine.

Analis saat ini menetapkan target harga rata-rata 70,73 USD untuk saham Moderna (median: 57,12 USD), yaitu -68,1 % terhadap harga terbaru. Konsensus didasarkan pada 33 peringkat analis.

31 analis saat ini menilai saham Moderna: 10 merekomendasikan beli, 17 tahan, dan 4 jual. Untuk 2026, analis memperkirakan Moderna menghasilkan pendapatan 2,10 miliar USD dan laba per saham -8,39 USD.

Dengan kurs saat ini, saham Moderna diperdagangkan pada 198,06 EUR (221,72 USD).

Saham Moderna (MRNA) tercatat di 13 bursa, termasuk: NYSE (MRNA), London (0A45.L), SIX (Zürich) (0QF.SW), XETRA (0QF.DE), Frankfurt (0QF.F), München (0QF.MU), Stuttgart (0QF.SG), Düsseldorf (0QF.DU).

Moderna Inc is a biotechnology company focused on the development and production of mRNA therapeutics and vaccines. The company was founded in 2010 and is headquartered in Cambridge, Massachusetts, USA. The core divisions of Moderna Inc include research and development, production, and marketing of mRNA-based therapeutics and vaccines. In the field of research and development, Moderna Inc is working to discover and develop new therapies and vaccines for a variety of diseases. The company has a broad range of therapy areas such as immuno-oncology, infectious diseases, rare diseases, autoimmune diseases, and cardiovascular diseases. Moderna Inc's product line includes mRNA-based therapeutics and vaccines. The company has already conducted several clinical trials in various therapy areas, including cancer, heart attack, and influenza. The company has also developed and produced vaccines against COVID-19, which have already been approved by many countries and used by millions of people worldwide. Moderna Inc also operates a production facility in Massachusetts, USA. The company has a proven ability to rapidly and on a large scale produce mRNA-based products, enabling it to quickly respond to epidemics and pandemics, as was the case with the COVID-19 pandemic. Moderna Inc's business model is based on the commercialization of mRNA-based therapeutics and vaccines. The company leverages its advanced technology and state-of-the-art production processes to develop fast and effective solutions for fighting diseases. The company has also formed partnerships with other companies, government agencies, and universities around the world to share and expand its technology and expertise. Moderna Inc is a publicly traded company listed on the Nasdaq stock exchange in the USA. The company has a strong financial structure and has a wide range of investors and partners worldwide. Overall, Moderna Inc has an innovative and promising business model. By developing and producing mRNA-based products, the company is contributing to fighting a wide range of diseases and improving the well-being of people worldwide. With its strong market position and advanced technology, the company is well-positioned to continue growing and succeeding in the future.

Pendapatan diperkirakan dari Moderna adalah 2,10 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari Moderna adalah -3,29 miliar USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) Moderna saat ini adalah -26,43. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham Moderna.

Rasio harga-terhadap-penjualan (PSR) Moderna saat ini adalah 41,37. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham Moderna.

Skor Kualitas AlleAktien untuk Moderna adalah 2/10.

ISIN dari Moderna adalah US60770K1079. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari Moderna adalah A2N9D9. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari Moderna adalah MRNA. Simbol ticker digunakan untuk memperdagangkan saham Moderna di bursa saham.

Nilai WajarTerminal
226,15 USD
Penilaian Berlebihan/KurangTerminal
Dinilai secara wajar
Sektor
Industri
Bioteknologi
Jumlah Saham
Karyawan
Pendapatan per Karyawan
413.617,02 USD
Pertumbuhan Pendapatan Ø5 Tahun
Pertumbuhan EBIT Ø5 Tahun
Pertumbuhan Laba Bersih Ø5 Tahun
Situs Web modernatx.com
Mata Uang
USD
Penawaran Umum Perdana
7 Des 2018
ISIN
US60770K1079
CUSIP
60770K107
SEDOL
BGSXTS3
Kapitalisasi Pasar
Kisaran 52 Minggu
Rasio PEG
—
P/E 2026
-26,43
P/E 2027
-46,79
P/E 2028
-78,06
P/E 2029
623,63
P/E 2030
62,97
P/S
41,37
EV/EBIT
—
Rasio P/B
10,01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-30,48 %
Terakhir diperbarui 3 Nov 2026, 03.15

Moderna Ticker

BERLIN · 0QF.BEDÜSSELDORF · 0QF.DUFRANKFURT · 0QF.FHAMBURG · 0QF.HMLONDON · 0A45.LMILAN · 1MRNA.MIMÜNCHEN · 0QF.MUNASDAQ · MRNANEW YORK · MRNASIX · 0QF.SWSTUTTGART · 0QF.SGWINA · MRNA.VI

Moderna FIGI

MRNA:US · BBG003PHHZT1MRNA:UA · BBG00MJW66D6MRNA:UC · BBG00MJW66F4MRNA:UN · BBG00MJW66H2MRNA:UP · BBG00MJW66J0MRNA:UB · BBG00MJW66L7MRNA:UM · BBG00MJW66N5MRNA:UX · BBG00MJW66P3MRNA:UD · BBG00MJW66V6MRNA:UW · BBG00MJW66X4MRNA:UF · BBG00MJW66Y3MRNA:VY · BBG00MJW66Z2

Semua metrik fundamental dan analisis mendalam Moderna

Analisis saham kami untuk saham Moderna mencakup kalkulasi keuangan penting seperti pendapatan, keuntungan, P/E ratio (P/E), P/S ratio (P/S), EBIT, serta informasi tentang dividen. Selain itu, kami juga mengamati aspek-aspek seperti saham, kapitalisasi pasar, utang, ekuitas, dan kewajiban dari Moderna. Jika Anda mencari informasi lebih rinci tentang topik-topik ini, kami menawarkan analisis terperinci di subhalaman kami.